In Vitro Activity of Ceftolozane/tazobactam and Ceftazidime/avibactam Against Carbapenemase-producing Pseudomonas aeruginosa
Journal Title: Mediterranean Journal of Infection, Microbes and Antimicrobials - Year 2019, Vol 8, Issue 1
Abstract
Introduction: The emergence of multidrug-resistant (MDR) and extensively drug-resistant strains of Pseudomonas aeruginosa in recent years has become a major issue due to treatment difficulties as well as high morbidity and mortality rates. Treatment options for infections caused by these microorganisms are very limited. Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (CZA) are recently developed cephalosporin/beta-lactamase inhibitor combinations for the treatment of infections caused by MDR P. aeruginosa strains. The aim of this study was to investigate the in vitro efficacy of C/T and CZA against MDR P. aeruginosa strains and to compare the in vitro efficacy of these two drugs. Materials and Methods: Thirty-two MDR P. aeruginosa isolates were included in the study. Identification and antimicrobial susceptibilities of the strains were performed using a VITEK 2® automated system. The efficacy of CZA and C/T was determined by the gradient strip test (Liofilchem MIC strip test, Italy). Modified carbapenemase inactivation method was used to detect carbapenemase production in all strains. Results: Rates of antibiotic resistance in the isolates were 78% for amikacin, 96.8% for levofloxacin, 90.6% for ciprofloxacin, 71.8% for gentamicin, and 78% for netilmicin. Ceftazidime/avibactam resistance was detected in 7 (21.8%) of the isolates and C/T resistance in 10 (31.2%). All strains with resistance to CZA also had resistance to C/T. Three strains were resistant to C/T but susceptible to CZA. Carbapenemase production was positive in all strains. Conclusion: The results of this study indicate that CZA and C/T may be an alternative treatment for some of the carbapenem-resistant P. aeruginosa infections. Further in vitro and in vivo studies are needed to evaluate the effectiveness of these new treatment options against the increasing threat of MDR P. aeruginosa.
Authors and Affiliations
Özlem AYDEMİR, Hüseyin Agah TERZİ, Mehmet KÖROĞLU, Mustafa ALTINDİŞ
Keywords
Related Articles
- EP ID EP689266
- DOI 10.4274/mjima.galenos.2019.2019.5
- Views 178
- Downloads 0
Analysis of Patients with Central Nervous System Infection at Our Clinic: Five-year Results
Introduction: This study aimed to determine the epidemiological data, clinical and laboratory findings, morbidity, and mortality of patients with central nervous system infection (CNSI). Materials and Methods: Patients...
Acinetobacter baumannii Biofilm: Intervening Factors, Persistence, Drug Resistance, and Strategies of Treatment
Acinetobacter baumannii (A. baumannii) is a Gram-negative opportunistic and nosocomial pathogen that is associated with most of the hospital epidemics. Its success can be directly attributed to its ability to survive und...
An Unusual Case of Orf with Erythema Multiforme and Vesiculo-bullous Lesions after Eid al-Adha
No Abstract
A Case Report of Rabies with Long Incubation: Importance in terms of Public Health
No Abstract
Mystery of Immune Response in Relapsed Brucellosis: Immunophenotyping and Multiple Cytokine Analysis
Introduction: Brucella spp. are intracellular bacteria that may cause acute, subacute and chronic infections. Despite optimum antibiotic treatment, relapse of brucellosis occurs in some patients. There is less amount of...